As an example, patient 21556, who carries a germline mutation in BRCA1, could be potentially eligible for PARPi therapy, but the targeted analysis of cfDNA at the time of diagnosis revealed the presence of two pathogenic variants in the TP53BP1 gene not detected in the tumor lesions analyzed. The gene discussed is TP53BP1; the disease is neoplasm.